1The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study [ J ]. Circulation, 1979,60(2) : 427-439.
2Rifai N, Cooper GR, Brown WV, et al. Clinical Chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years[ J]. Clin Chem, 2004,50 (10): 1861-1870.
3Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type H Coronary Intervention Study [ J ]. Circulation, 1984,69(2) : 313-324.
4The Lipid Research Clinics Coronary Primary Preven- tion Trial results. I. Reduction in incidence of coronary heart disease [ J]. JAMA, 1984,251 ( 3 ) : 351-364.
5The Lipid Research Clinics Coronary Primary Preven- tion Trial results. Ⅱ. The relationship of reduetion in incidenee of coronary heart disease to cholesterol lowering [ J ]. JAMA, 1984,251 ( 3 ) : 365-374.
6Carleton RA,Dwyer J,Finberg L,et al. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung,and Blood Institute, National Institutes of Health[ J ]. Circulation, 1991,83 (6) : 2154-2232.
7Summary of the second report of the National Chole- sterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 11 ) [ J ]. JAMA, 1993,269 ( 23 ) : 3015-3023.
8Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evalua- tion, and treatment of high blood cholesterol in adults ( adult treatment panel Ⅱ ) final report [ J ]. Circula- tion,2002,106(25 ) : 3143-3421.
9Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel m Guide- lines [ J ]. Circulation, 2004,110 (2) : 227-239.
10Brown WV, Myers GL, Sniderman AD, et al. Should we use apoB for risk assessment and as a target for treatment[J]. J Clin Lipidol,2010,4(3) : 144-151.
